- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Malignant Neoplasm, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, cytarabine, mitoxantrone hydrochloride, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 10,395
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Basal Cell Carcinoma
- Interventions
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Drug
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Apple Valley, California • Colton, California • Fremont, California + 11 more
- Conditions
- Hemophilia A
- Interventions
- valoctocogene roxaparvovec
- Biological
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
- Interventions
- NT-501, Sham
- Drug · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cystic Fibrosis
- Interventions
- Doxycycline, placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
- Interventions
- Genetic screening
- Genetic
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Congenital Anomaly, Pediatric Cancer
- Interventions
- Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- ATI-502
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Encinitas, California • San Diego, California • Fridley, Minnesota + 3 more
- Conditions
- Glycogen Storage Disease Type Ia
- Interventions
- No Intervention
- Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 9
- States / cities
- Orange, California • Denver, Colorado • Hartford, Connecticut + 6 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hemophilia B
- Interventions
- CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 138 Months to 206 Months · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 6
- States / cities
- Orange, California • San Diego, California • Gainesville, Florida + 3 more
- Conditions
- Fabry Disease
- Interventions
- Migalastat HCl 150 mg
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- Acoramidis (AG10)
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
- Conditions
- Down Syndrome
- Interventions
- Gross motor intervention, gross and fine motor intervention
- Behavioral
- Lead sponsor
- Georgia State University
- Other
- Eligibility
- 7 Months to 36 Months
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Disease
- Interventions
- Vonapanitase, Placebo
- Drug
- Lead sponsor
- Proteon Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
- Conditions
- Gout
- Interventions
- Patient Navigation
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Sickle Cell Disease
- Interventions
- Placebo, HQK-1001
- Drug
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 8
- States / cities
- Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
- Conditions
- Hypoplastic Left Heart Syndrome, Tetralogy of Fallot
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Day to 1 Year
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia
- Interventions
- Marstacimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
- Interventions
- rhIGF-I/rhIGFBP-3
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 2 Years to 18 Years
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 2 Months to 115 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1994
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
- Conditions
- Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Dystrophica
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California